Maxwell Biosciences, an Austin, Texas-based developer of next generation virucides, secured a major investment from pharmaceutical investor-entrepreneur David Evans Shaw, Managing Partner of Black Point Group.
The amount of the deal was not disclosed.
The investment will be used to advance Maxwell’s CLAROMER™ brand anti-infectives program towards clinical stage development.
Led by founder and CEO Joshua McClure and Chairman of the Board Stephen Pearse, Maxwell Biosciences develops drugs designed to be effective against rapidly evolving, widespread viruses. Its CLAROMER™ brand anti-infectives destroy a broad spectrum of viruses, as shown in preclinical studies and imaging of viral structures. They have been shown in preclinical studies to destroy a broad spectrum of viruses including rapidly evolving novel Coronavirus strains, Hepatitis B and C, Herpes Simplex Virus, and Influenza A virus. They have also been shown to be well tolerated in human tissues and in vivo animal studies. The technology is protected by granted patents.